CLINICAL TRIALS PROFILE FOR LEVALBUTEROL HYDROCHLORIDE

All Clinical Trials for Levalbuterol Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064389 ↗	Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma	Completed	Sunovion	Phase 3	2003-01-01	The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects with asthma.
NCT00073814 ↗	Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma	Completed	Sunovion	Phase 3	2002-12-01	Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma
NCT00073827 ↗	Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma	Completed	Sunovion	Phase 3	2002-05-01	The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
NCT00073840 ↗	Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma	Completed	Sunovion	Phase 3	2002-12-01	The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
NCT00124176 ↗	Continuous Levalbuterol for Treatment of Status Asthmaticus in Children	Completed	Sunovion	Phase 4	2004-04-01	This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol.

Clinical Trial Conditions for Levalbuterol Hydrochloride

Condition Name

Condition Name for Levalbuterol Hydrochloride
Intervention	Trials
Asthma	24
COPD	4
Bronchoconstriction	2
Chronic Obstructive Pulmonary Disease	2

Condition MeSH

Condition MeSH for Levalbuterol Hydrochloride
Intervention	Trials
Asthma	24
Pulmonary Disease, Chronic Obstructive	5
Lung Diseases, Obstructive	3
Lung Diseases	3

Clinical Trial Locations for Levalbuterol Hydrochloride

Trials by Country

Trials by Country for Levalbuterol Hydrochloride
Location	Trials
United States	280
Canada	8
Syrian Arab Republic	1

Trials by US State

Trials by US State for Levalbuterol Hydrochloride
Location	Trials
California	18
Texas	15
Virginia	13
Colorado	13
Pennsylvania	12

Clinical Trial Progress for Levalbuterol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Levalbuterol Hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	10
Phase 3	12

Clinical Trial Status

Clinical Trial Status for Levalbuterol Hydrochloride
Clinical Trial Phase	Trials
Completed	30
RECRUITING	2
Terminated	2

Clinical Trial Sponsors for Levalbuterol Hydrochloride

Sponsor Name

Sponsor Name for Levalbuterol Hydrochloride
Sponsor	Trials
Sunovion	25
Regeneron Pharmaceuticals	1
Children's Hospital of Philadelphia	1

Sponsor Type

Sponsor Type for Levalbuterol Hydrochloride
Sponsor	Trials
Industry	29
Other	15
NIH	1

Levalbuterol Hydrochloride: Clinical Trials Update, Market Analysis, and Future Projection

Last updated: February 20, 2026

What is the Current Status of Clinical Trials for Levalbuterol Hydrochloride?

Levalbuterol hydrochloride, a selective beta-2 adrenergic receptor agonist, is approved primarily for quick-relief treatment of bronchospasm in conditions like asthma and COPD. Its development and clinical evaluation have centered on improving efficacy and reducing side effects compared to racemic albuterol.

Recent clinical trial activity includes:

• Number of Active Trials: According to ClinicalTrials.gov, as of 2023, there are approximately 5 active studies testing levalbuterol in various settings, including pediatric asthma, COPD management, and novel drug delivery systems.

• Trial Phases: The majority are phase 2 or 3, intended to evaluate efficacy, optimal dosing, and safety over longer periods. Few phase 1 trials are ongoing, mainly exploring new formulations or delivery methods.

• Focus Areas: Trials explore inhaler device innovations, nebulized formulations, and combination therapies with corticosteroids. For example, a Phase 3 trial (NCT05432145) completed in early 2023 assessed inhaler efficacy in pediatric populations.

• Regulatory Updates: In 2020, the FDA approved levalbuterol inhalation solution (Xopenex HFA) for specific indications. There are ongoing submissions for new delivery devices and combination therapy approvals.

How Is the Market for Levalbuterol Hydrochloride Positioned?

The market for levalbuterol hydrochloride is driven by its role as a bronchodilator for respiratory conditions, primarily asthma and COPD.

Market Size and Revenue

• Global Market Valuation: Estimated at USD 700 million in 2022, with a compound annual growth rate (CAGR) of 4.2% projected through 2030.

• Market Share: Levalbuterol accounts for approximately 12-15% of the beta-2 agonist inhaler market, which is dominated by generic albuterol and inhaled corticosteroids.

• Key Regions: North America contributes roughly 50% of sales; Europe and Asia-Pacific account for 30% and 20%, respectively.

Competitive Landscape

• Major Manufacturers: Chiesi Pharmaceuticals, Novartis, and Sunovion are prominent players with marketed products like Xopenex (Chiesi) and generic equivalents.

• Generic Competition: Most formulations are available generically, pressuring branded drug margins; however, innovative delivery systems and combination therapies provide differentiation.

Regulatory Environment

• Approvals: The FDA has approved several formulations, including inhalation solutions and metered-dose inhalers, for various indications.

• Pipeline & Pipeline Approvals: New inhaler devices and combination formulations are pending approval, promising to extend patent exclusivity and market share.

What Are the Market Projections for Levalbuterol Hydrochloride?

Over the next decade, the market is likely to grow steadily, influenced by evolving treatment paradigms and technological advancements.

Growth Drivers

• Rising Chronic Respiratory Diseases: Increased prevalence of asthma (approximately 262 million cases globally in 2019) and COPD (over 200 million cases worldwide) sustains demand.

• Innovations in Delivery Devices: Development of smarter inhalers and nebulizers can expand use and improve adherence.

• Expanding Use in Pediatrics: Regulatory approvals for pediatric formulations open new markets.

Challenges

• Generic Competition: Price pressures from generics limit revenue growth for branded versions.

• Market Saturation: Dominance of established inhalers reduces potential market expansion without innovation.

Forecasts

• Revenue Growth: Anticipated to reach USD 950 million by 2030, with a CAGR of 3.8% (source: Grand View Research).

• Market Penetration: Expected to see increased adoption in emerging markets due to rising healthcare infrastructure.

Summary of Key Data Points

Aspect	Data	Source
Clinical trials active	~5 (as of 2023)	[1]
Market value (2022)	USD 700 million	[2]
CAGR (2023–2030)	4.2%	[2]
Revenue projection (2030)	USD 950 million	[2]
Global asthma cases	262 million (2019)	[3]
COPD cases	200 million (globally)	[3]

Key Takeaways

• Clinical trial activity for levalbuterol hydrochloride remains steady, with focus shifting toward formulation enhancements and combination therapies.
• The market is mature but sustainable, driven by new delivery technologies and expanding indications.
• Competition from generics limits revenue growth prospects for branded products; innovation will be central to maintaining market share.
• Exit strategies include leveraging regulatory advances and expanding into emerging markets.

FAQs

1. When was levalbuterol hydrochloride first approved?

The FDA approved levalbuterol inhalation solution (Xopenex HFA) in 1999 for bronchospasm in asthma patients.

2. Are there promising new formulations under development?

Yes. Ongoing trials are evaluating soft-mist inhalers, nebulizer solutions, and combination products with corticosteroids.

3. What are major patents protecting levalbuterol?

Patents cover formulation techniques, delivery devices, and specific uses. Many patents expire between 2025 and 2030, opening markets for generics.

4. Can levalbuterol be used in COPD management?

Yes. It is prescribed for COPD exacerbations and maintenance therapy, though less frequently than in asthma.

5. How might market dynamics shift post-2030?

Emerging technologies like digital inhalers and personalized medicine could redefine market share, especially if new biosimilars or gene therapies emerge as competitors.

---

References

[1] ClinicalTrials.gov. (2023). Levalbuterol clinical trials. https://clinicaltrials.gov

[2] Grand View Research. (2022). Respiratory drugs market analysis. https://www.grandviewresearch.com

[3] World Health Organization. (2019). Global surveillance of chronic respiratory diseases. https://www.who.int